Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Desai A. Epithelial ovarian cancer: an overview. World J Transl Med. 2014;3(1):1.

Article  PubMed  PubMed Central  Google Scholar 

Deb B, Uddin A, Chakraborty S. miRNAs and ovarian cancer: an overview. J Cell Physiol. 2018;233(5):3846–54.

Article  CAS  PubMed  Google Scholar 

Roett MA, Evans P. Ovarian cancer: an overview. Am Fam Physician. 2009;80(6):609–16.

PubMed  Google Scholar 

Klotz DM, Wimberger P. Cells of origin of ovarian cancer: ovarian surface epithelium or fallopian tube? Arch Gynecol Obstet. 2017;296(6):1055–62.

Article  PubMed  Google Scholar 

Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res. 2013;19(5):961–8.

Article  CAS  PubMed  Google Scholar 

Longuespée R, Boyon C, Desmons A, Vinatier D, Leblanc E, Farré I, et al. Ovarian cancer molecular pathology. Cancer Metastasis Rev. 2012;31(3–4):713–32.

Article  PubMed  Google Scholar 

Jelovac D, DK A. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61(3):183–203.

Article  PubMed  PubMed Central  Google Scholar 

Gong S, Li Q, Jeter CR, Fan Q, Tang DG, Liu B. Regulation of NANOG in cancer cells. Mol Carcinog. 2015;54(9):679–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen W, Dong J, Haiech J, Kilhoffer MC, Zeniou M. Cancer stem cell quiescence and plasticity as major challenges in cancer therapy. Stem Cells Int. 2016;2016:1–16.

Google Scholar 

Vinogradov S, Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine. 2012;7(4):597–615.

Article  CAS  PubMed  Google Scholar 

Liu HD, Xia BR, Jin MZ, Lou G. Organoid of ovarian cancer: genomic analysis and drug screening. Clin Transl Oncol. 2020;22(8):1240–51. https://doi.org/10.1007/s12094-019-02276-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sonbol MB, Ahn DH, Bekaii-Saab T. Therapeutic targeting strategies of cancer stem cells in gastrointestinal malignancies. Biomedicines. 2019;7(1):147.

Article  Google Scholar 

Jeter CR, Yang T, Wang J, Chao H, Dean G, Park S, et al. NANOG in cancer stem cells and tumor development: an update and outstanding questions. Stem Cells. 2016;33(8):2381–90.

Article  Google Scholar 

OzdemirKutbay N, BirayAvci C, SarerYurekli B, Caliskan Kurt C, Shademan B, Gunduz C, Erdogan M. Effects of metformin and pioglitazone combination on apoptosis and AMPK/mTOR signaling pathway in human anaplastic thyroid cancer cells. J Biochem Mol Toxicol. 2020;34(10): e22547.

Article  CAS  Google Scholar 

Sogutlu F, Kayabasi C, Yelken BO, Asik A, Gasimli R, Kipcak S, Susluer SY, Avci CB, Gunduz C. The evaluation of effect of aurora kinase inhibitor CCT137690 in melanoma and melanoma cancer stem cell. Anti-Cancer Agents in Med Chem. 2021;21(12):1564–74.

Article  CAS  Google Scholar 

Foty R. A simple hanging drop cell culture protocol for generation of 3D spheroids. JoVE. 2011;51: e2720.

Google Scholar 

Ottevanger PB. Ovarian cancer stem cells more questions than answers. Seminars in Cancer Biol. 2017;44:67–71.

Article  CAS  Google Scholar 

Budiana ING, Angelina M, Pemayun TGA. Ovarian cancer: pathogenesis and current recommendations for prophylactic surgery. J Turkish-German Gynecol Assoc. 2019;20(1):47–54.

Article  Google Scholar 

Cho KR, Shih IM. Ovarian cancer. Annu Rev Pathol Mech Dis. 2009;4(4):287–313.

Article  CAS  Google Scholar 

Hubbard JM, Grothey A. Napabucasin: an update on the first-in-class cancer stemness inhibitor. Drugs. 2017;77(10):1091–103.

Article  CAS  PubMed  Google Scholar 

Jin X, Jin X, Kim H. Cancer stem cells and differentiation therapy. Tumor Biol. 2017;39(10):1–11.

Article  Google Scholar 

Aponte PM, Caicedo A. Stemness in cancer: Stem cells, cancer stem cells, and their microenvironment. Stem Cells Int. 2017;2017:1–17.

Article  Google Scholar 

Lathia JD, Liu H. Overview of cancer stem cells and stemness for community oncologists. Target Oncol. 2017;12(4):387–99.

Article  PubMed  PubMed Central  Google Scholar 

Jeter CR, Yang T, Wang J, Chao HP, Tang DG. Concise review: NANOG in cancer stem cells and tumor development: an update and outstanding questions. Stem Cells. 2015;33(8):2381–90.

Article  CAS  PubMed  Google Scholar 

Jia Z, Zhang Y, Yan A, Wang M, Han Q, Wang K, et al. 1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells. Cell Death Dis. 2020. https://doi.org/10.1038/s41419-020-02908-w.

Article  PubMed  PubMed Central  Google Scholar 

Mahalaxmi I, Devi SM, Kaavya J, Arul N, Balachandar V, Santhy KS. New insight into NANOG: a novel therapeutic target for ovarian cancer (OC). Eur J Pharmacol. 2019;852:51–7. https://doi.org/10.1016/j.ejphar.2019.03.003.

Article  CAS  PubMed  Google Scholar 

Liu S, Sun J, Cai B, Xi X, Yang L, Zhang Z, et al. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer. Tumor Biol. 2016;37(7):9671–80. https://doi.org/10.1007/s13277-016-4848-x.

Article  CAS  Google Scholar 

Siu MKY, Wong ESY, Kong DSH, Chan HY, Jiang L, Wong OGW, et al. Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers. Oncogene. 2013;32(30):3500–9.

Article  CAS  PubMed  Google Scholar 

Cote GM, Chau NG, Spira AI, Edenfield WJ, Laurie SA, Richards DA, Richey SL, Gao Y, Li Y, Li W, Hitron M. A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor in advanced head and neck cancer. J Clin Oncol. 2017;35:6032.

Article  Google Scholar 

Cote GM, Edenfield WJ, Laurie SA, Chau NG, Becerra C, Spira AI, Li Y, Li W, Hitron M, Li C. A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor, in advanced adenoid cystic carcinoma. J Clin Oncol. 2017;35:6036.

Article  Google Scholar 

El-Rayes BF, Richards DA, Cohn AL, Richey SL, Feinstein T, Kundranda MN, El-Khoueiry AB, Melear JM, Braiteh FS, Hitron M, Ortuzar WF. BBI608–503–103HCC: A phase Ib/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC). J Clin Oncol. 2017;35:4077.

Article  Google Scholar